| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1988.6.8.1328 |
| P953 | full work available at URL | http://intl.jco.org/cgi/content/abstract/6/8/1328 |
| https://ascopubs.org/doi/pdfdirect/10.1200/JCO.1988.6.8.1328 | ||
| P698 | PubMed publication ID | 3411344 |
| P50 | author | Moshe Talpaz | Q87650933 |
| P2093 | author name string | J. U. Gutterman | |
| R. Kurzrock | |||
| B. Feinberg | |||
| S. Saks | |||
| M. Blick | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| oncology | Q162555 | ||
| P304 | page(s) | 1328-1334 | |
| P577 | publication date | 1988-08-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients | |
| P478 | volume | 6 |
| Q55001725 | A New Venue of TNF Targeting. |
| Q55241476 | A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. |
| Q38015061 | Biological response modifiers in the management of patients with breast cancer |
| Q42482850 | Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q36081325 | Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. |
| Q36363709 | Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality |
| Q37068894 | Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. |
| Q36422849 | Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors |
| Q34479801 | Cytokine deregulation in cancer |
| Q67993236 | Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations |
| Q39123611 | Dyslipidemia in systemic lupus erythematosus |
| Q84845719 | Early effect of hepatic artery TNF-alpha infusion on systemic hemodynamics and inflammation: a dose-response study in pigs |
| Q33356537 | Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine |
| Q44586795 | Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus |
| Q40785400 | Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region |
| Q43710400 | Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region |
| Q35925611 | Gene therapy strategies to improve the effectiveness of cancer radiotherapy |
| Q71988414 | High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer |
| Q39227872 | High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation |
| Q42150777 | High serum levels of TNF-α after its administration for isolation perfusion of the limb |
| Q38221692 | Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer |
| Q33177384 | In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats |
| Q40641645 | Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity |
| Q64906046 | Inflammatory Signaling in Hypertension: Regulation of Adrenal Catecholamine Biosynthesis. |
| Q41703227 | Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies |
| Q41353348 | Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells |
| Q36869456 | Interleukins. Clinical pharmacokinetics and practical implications |
| Q35711884 | Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma |
| Q33180138 | Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response |
| Q41911282 | Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan |
| Q36838339 | Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience |
| Q41062002 | Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. |
| Q36421633 | Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion |
| Q33180936 | Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats |
| Q54064832 | NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. |
| Q30832764 | NF-κB signalling and cell fate decisions in response to a short pulse of tumour necrosis factor. |
| Q43688712 | Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction |
| Q33380199 | Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor |
| Q40754298 | Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy |
| Q40582599 | Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis |
| Q36764997 | Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results |
| Q67720624 | Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases |
| Q37054005 | Role of Eicosanoids and the Cytokine Network in Transmembrane Signaling in Vascular Cells |
| Q40436403 | Signal Transduction in Atherosclerosis: Second Messengers and Regulation of Cellular Cholesterol Trafficking |
| Q29616428 | Signalling pathways of the TNF superfamily: a double-edged sword |
| Q60060706 | Squalene synthase: Structure and regulation |
| Q37167995 | Systemic lupus erythematosus and cardiovascular disease. |
| Q35640180 | Systemic use of tumor necrosis factor alpha as an anticancer agent |
| Q53923210 | TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. |
| Q39529070 | TNF-dependent signaling pathways in liver cancer: promising targets for therapeutic strategies?. |
| Q45855568 | TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene |
| Q91709254 | Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade |
| Q99557580 | Targeting co-stimulatory molecules in autoimmune disease |
| Q35196479 | The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells |
| Q39439223 | The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress |
| Q45882007 | Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity |
| Q40761921 | Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha |
| Q37965274 | Tumor necrosis factor: an update on basic research and clinical applications |
| Q40665218 | Tumour necrosis factor: the decline and fall of a biological agent and its resurrection |
| Q39345885 | Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo |
| Q44712586 | Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes |
Search more.